Fulgent Genetics Reports Revenue Growth Amid Financial Losses and Optimistic Future Projections

Fulgent Genetics Reports Strong Growth in Laboratory Services Amid Financial Losses

Fulgent Genetics, Inc., a technology-driven company specializing in laboratory services and therapeutic development, showcases notable growth in its core revenue for the third quarter of 2024. For the period ending September 30, Fulgent records total revenue of $71.7 million, marking a 9% increase year-over-year when excluding income from COVID-19 testing. This uptick in revenue underscores the company’s pivot towards strengthening its laboratory services, which has been a focal point of its strategy as demand for diverse genetic testing continues to rise. Despite this revenue growth, Fulgent faces challenges, reporting a GAAP loss of $14.6 million, or $0.48 per share. However, the company also highlights a non-GAAP income of $9.4 million, translating to $0.31 per share, alongside an adjusted EBITDA income of $0.4 million.

CEO Ming Hsieh emphasizes the positive momentum in the Laboratory Services sector, noting growth across all divisions. This optimistic outlook is bolstered by preliminary results from the Phase 2 clinical trial of FID-007, a therapeutic candidate for Head and Neck Cancer. The trial’s results could potentially position Fulgent as a key player in the oncology space, allowing the company to leverage its technological capabilities not only for testing but also for treatment development. Such advancements are critical, as the healthcare landscape increasingly values integrated solutions that combine diagnostics with therapeutic options, aligning with Fulgent’s long-term vision.

Looking ahead, Fulgent projects a core revenue of approximately $280 million for the entirety of 2024, indicating confidence in continued growth. The company anticipates improvements in both GAAP and non-GAAP losses per share, with GAAP losses expected to decrease from about $1.95 to $1.70 per share and non-GAAP figures shifting from a loss of $0.30 per share to a profit of $0.33 per share. This projected financial improvement, coupled with a significant liquidity position of $815.4 million as of September 30, positions Fulgent well for future endeavors in the rapidly evolving genetic testing and therapeutic development landscape.

In addition to its financial performance, Fulgent prepares for a conference call at 8:30 AM ET today to discuss these results with the investment community. This engagement reflects the company's commitment to transparency and communication with stakeholders as it navigates its growth trajectory. With a projected cash reserve of approximately $800 million by the end of 2024, Fulgent is well-positioned to invest in innovative projects and expand its market presence in the coming years.